EUVIMEDOpdag EUVIMED
Crossref

A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo

Ling Zhong, Wanlin Zhang, Rui Xiao, Huiping He, Qian Wu, Junping Hong, Mu-Sheng Zeng iD, Qinjian Zhao, Qingbing Zheng, Yi-Xin Chen iD, Xiao Zhang iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c00701 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2025. Written by Ling Zhong and 10 co-authors. Institution: College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China. Major MEDLINE topics: Antibodies, Neutralizing, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Vaccines, Virus-Like Particle. Cited 1 times so far (Crossref); 43 references. Funded by: Chongqing Municipal Education Commission, Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Chongqing Municipality.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Epstein-Barr Virus (EBV) as the first characterized tumorigenic virus in humans causes heavy disease burdens. An effective vaccine is urgently needed to block EBV infection. Glycoprotein B (gB) is the essential fusogen for EBV infection of all susceptible cell types. We previously demonstrated that neutralizing antibody 3A3 targeting gB effectively blocked EBV infection in a humanized mouse model, indicating that the epitope recognized by 3A3 is the potential immunogen candidate. Hence, we rationally designed a chimeric virus-like particle (cVLP) vaccine based on the hepatitis B core antigen (HBc149) to display gB peptide, αB, recognized by 3A3 (149-αB cVLP). The engineered 149-αB cVLP vaccine self-assembled into spherical particles presenting multiple copies of αB peptide. The 149-αB cVLP vaccine induced much higher antibody titers against αB peptides than gB protein immunization. Importantly, sera antibodies elicited by the 149-αB cVLP vaccine more efficiently blocked EBV infection and membrane fusion of epithelial cells and B cells. Sera from 149-αB cVLP vaccine-immunized rabbits conferred 100% protection against EBV infection in a humanized mouse model. We demonstrated that the 149-αB cVLP vaccine induced potent antigen-specific protective immune responses and shed light on the research of peptide-based vaccines against EBV infection.

Subjects

MeSH terms (MEDLINE)

Antibodies, NeutralizingEpstein-Barr Virus InfectionsHerpesvirus 4, HumanVaccines, Virus-Like ParticleImmunodominant EpitopesViral Envelope ProteinsAnimalsHumansRabbitsMiceAntibodies, Viral

Author keywords

Chimeric virus-like particle vaccineEpstein-Barr virusHBc-149Neutralizing antibodiesgB

Substances

Antibodies, NeutralizingVaccines, Virus-Like ParticleImmunodominant EpitopesAntibodies, ViralViral Envelope Proteins

Authors and institutions

  • College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
  • Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
  • Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, PR China.
  • State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Collab…

ORCID profiles: Mu-Sheng Zeng, Yi-Xin Chen, Xiao Zhang

Funding

  • Chongqing Municipal Education Commission
  • Ministry of Science and Technology of the People's Republic of China
  • Natural Science Foundation of Chongqing Municipality
  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China

Cite

APA

Zhong, L., Zhang, W., Xiao, R., He, H., Wu, Q., Hong, J., Zeng, M. S., Zhao, Q., Zheng, Q., Chen, Y. X., & Zhang, X. (2025). A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c00701

Vancouver

Zhong L, Zhang W, Xiao R, He H, Wu Q, Hong J, et al. A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c00701

BibTeX
@article{Zhong2025,
  author = {Zhong, Ling and Zhang, Wanlin and Xiao, Rui and He, Huiping and Wu, Qian and Hong, Junping and Zeng, Mu-Sheng and Zhao, Qinjian and Zheng, Qingbing and Chen, Yi-Xin and Zhang, Xiao},
  title = {A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c00701}
}
Start for free →